


ASD

Adult and Adolescent Spectrum of HIV Disease (ASD) Annual Summary Report 1990-2002

January 2004



Los Angeles County Department of Health Services
HIV Epidemiology Program

600 S. Commonwealth Ave., Suite 1920
Los Angeles, CA 90005
(Phone) (213) 351-8196
(Fax) (213) 487-9386
www.lapublichealth.org/hiv



BOARD OF SUPERVISORS

Gloria Molina	<i>First District</i>
Yvonne Brathwaite Burke	<i>Second District</i>
Zev Yaroslavsky	<i>Third District</i>
Don Knabe	<i>Fourth District</i>
Michael D. Antonovich	<i>Fifth District</i>

DEPARTMENT OF HEALTH SERVICES

Thomas L. Garthwaite, MD	Director and Chief Medical Director, Department of Health Services
Jonathan Fielding, MD, MPH	Director, Public Health Program and Health Officer
Paul A. Simon, MD, MPH	Director, Office of Health Assessment and Epidemiology
Gordon Bunch, MA	Director, HIV Epidemiology Program

ASD STAFF

Amy Rock Wohl, PhD	Principal Investigator
Mallory Witt, MD, Harbor/UCLA	Co-Investigator
William Towner, MD, Kaiser-Sunset	Co-Investigator
Andrea Kovacs, MD, LAC/USC	Co-Investigator
Kathleen Squires, MD, LAC/USC	Co-Investigator
Wendy Garland, MPH	Project Coordinator
Sharon Lu, MPH	Data Manager
Mary Vitale	Data Entry
Maria Lomeli	Data Entry
Ruben Lopez, Harbor/UCLA	Data Abstractor
Nancy Lusk, Kaiser-Sunset	Data Abstractor
Noemi Nagaoka, Kaiser-Sunset	Data Abstractor
Jamil Ahmed, LAC/USC	Data Abstractor
Mohammed Rahman, LAC/USC	Data Abstractor

**Los Angeles
Adult and Adolescent Spectrum of HIV Disease (ASD)
Annual Summary Report
January 2004**

Table of Contents

Introduction.....	1
Table 1: Demographic Characteristics and Vital Status.....	2
Table 2: AIDS Indicator Conditions.....	3
Figure 1: Trends in PCP, Esophageal Candidiasis, Herpes Simplex, Disseminated or Extrapulmonary TB/Pulmonary TB, and Cryptococcosis/Coccidioidomycosis/Histoplasmosis.....	4
Figure 2: Trends in MAC, KS, Wasting Syndrome, CMV and CMV Retinitis.....	5
Figure 3: Trends in Dementia, Cryptosporidiosis, Toxoplasmosis and Lymphoma..	5
Table 3: Non-AIDS Infections Present in \geq5% of Patients.....	6
Table 4: Non-AIDS Conditions Present in \geq5% of Patients.....	7
Table 5: Primary Malignant Neoplasms.....	8
Figure 4: Antiretroviral Therapy Regimens.....	9
Figure 5: Mortality Rates.....	10
Figure 6,7: Rate of Outpatient and Emergency Room Visits by Lowest Range of CD4 in a Given Year.....	11
Figure 8,9: Rate of Hospitalizations and Hospital Days by Lowest Range of CD4 in a Given Year.....	12
Figure 10: Lowest CD4 Count among ASD Patients in a Given Year, 1990-2002.....	13
Figure 11: Highest Viral Load among ASD Patients in a Given Year, 1995-2002.....	13

Suggested Citation: HIV Epidemiology Program, Los Angeles County Department of Health Services.
Adult and Adolescent Spectrum of HIV Disease (ASD) Annual Summary Report,
January, 2004: 1-13

Table 1. Demographic Characteristics of ASD Patients with Visits in the Past 24 Months¹

Characteristics	Male		Female		All	
	n	%	n	%	n	%
Age (at enrollment)						
13-19	12	1%	21	4%	33	2%
20-29	151	15%	142	29%	293	19%
30-39	491	47%	180	37%	671	44%
40-49	283	27%	100	21%	383	25%
50+	103	10%	43	9%	146	10%
Race/Ethnicity						
White	233	22%	42	9%	275	18%
African-American	284	27%	153	31%	437	29%
Latino	457	44%	278	57%	735	48%
Asian/Pacific Islanders	55	5%	8	2%	63	4%
AN/AI	6	1%	4	1%	10	1%
Other/Unknown	5	0%	1	0%	6	0%
HIV Risk Category						
MSM	689	66%	-	-	689	45%
IDU	62	6%	68	14%	130	9%
MSM/IDU	68	7%	-	-	68	4%
Heterosexual	45	4%	214	44%	259	17%
Others	27	3%	32	7%	59	4%
Unknown	149	14%	172	35%	321	21%
Country of Birth						
US	601	58%	208	43%	809	53%
US Dependency	10	1%	1	0%	11	1%
Foreign-born:	359	35%	269	55%	628	41%
(Mexico)	(208)	(58%)	(127)	(47%)	(335)	(53%)
(Central America)	(62)	(17%)	(96)	(36%)	(158)	(25%)
(Asian/PI)	(40)	(11%)	(6)	(2%)	(46)	(7%)
(Other/Unknown)	(49)	(14%)	(40)	(15%)	(89)	(14%)
Unknown	70	7%	8	2%	78	5%
Site of Care						
Harbor UCLA	602	58%	130	27%	732	48%
Kaiser Sunset	404	39%	30	6%	434	28%
LAC/USC	34	3%	326	67%	360	24%
Total	1,040	68%	486	32%	1,526	100%
Vital Status at Most Recent Interval²						
Alive and active	805	16%	391	30%	1,196	19%
Dead	2,035	42%	352	27%	2,387	39%
Relocated/Lost/Unkwn	1,943	40%	542	42%	2,485	40%
BEER ³	107	2%	20	2%	127	2%
Total	4,890	100%	1,305	100%	6,195	100%

¹ Includes the time period 01/01/2001 to 12/31/2002.

² Totals include all ASD patients.

³ Active BEER patients at the end of BEER's participation in ASD in January 2001.

Table 2. AIDS Indicator Conditions¹ for All ASD Patients in the Pre (1989-1995) and Post (1996-2002) HAART Era

Indicator Condition	1989-1995 (N=3,119)		1996-2002 (N=2,255)	
	N	%	N	%
Candidiasis, bronchi, trachea, or lungs	6	0.2%	2	0.1%
Candidiasis, esophageal	334	10.7%	179	7.9%
Invasive cervical cancer	1	0.0%	5	0.2%
Coccidioidomycosis, disseminated or extrapulmonary	9	0.3%	9	0.4%
Cryptococcosis, extrapulmonary	183	5.9%	114	5.1%
Cryptosporidiosis, chronic intestinal	117	3.8%	24	1.1%
Cytomegalovirus disease other than retinitis	165	5.3%	84	3.7%
Cytomegalovirus retinitis	303	9.7%	80	3.5%
HIV encephalopathy	147	4.7%	75	3.3%
Herpes simplex: chronic ulcers, pneumonitis or esophagitis	92	2.9%	30	1.3%
Histoplasmosis, disseminated or extrapulmonary	28	0.9%	20	0.9%
Isosporiasis, chronic intestinal	30	1.0%	15	0.7%
Kaposi's sarcoma	361	11.6%	94	4.2%
Lymphoma, Burkitt's	6	0.2%	5	0.2%
Lymphoma, immunoblastic	48	1.5%	26	1.2%
Lymphoma, primary in brain	24	0.8%	16	0.7%
Mycobacterium avium or M. kansasii, disseminated	344	11.0%	90	4.0%
M. tuberculosis, pulmonary	38	1.2%	66	2.9%
M. tuberculosis, disseminated or extrapulmonary	120	3.8%	55	2.4%
Mycobacterium, other or unidentified species	32	1.0%	20	0.9%
Pneumocystis carinii pneumonia	830	26.6%	351	15.6%
Pneumonia, recurrent	1	0.0%	26	1.2%
Progressive multifocal leukoencephalopathy	23	0.7%	14	0.6%
Salmonella septicemia, recurrent	5	0.2%	2	0.1%
Toxoplasmosis of the brain	121	3.9%	55	2.4%
Wasting syndrome	468	15.0%	171	7.6%
CD < 200 ul ²	694	22.3%	488	21.6%

¹ Based on the 1993 AIDS case definition.

² Includes only those without any other AIDS-defining condition.

Table 3. Other Infections¹ Present in >= 5% of Patients (N=1,526²), 1989-2002

Infection	N	%
Skin infection (excludes genital infection, Herpes zoster, syphilis)	561	37%
Genital/vaginal/cervical/penile infection or ulcer	516	34%
Thrush	496	33%
Bronchitis	392	26%
Urinary tract infection (UTI)	310	20%
Tinea infection	305	20%
Oral cavity/perioral (includes stomatitis, aphthous ulcer)	296	19%
Sinusitis/mastoiditis (infectious)	289	19%
Herpes zoster/shingles	283	19%
Upper respiratory infection	282	18%
Condyloma acuminatum	261	17%
Hepatitis	235	15%
Diarrhea (infectious)	211	14%
Pneumonia	194	13%
Gastrointestinal infection/gastritis	185	12%
Rectal infection (includes abscess or ulcer)	175	11%
Syphilis	156	10%
Pharyngitis	155	10%
Oral hairy leukoplakia	103	7%
Warts (excludes genital/condyloma)	95	6%
Otitis	89	6%
Eye infection	75	5%

¹ Includes conditions that are not part of the 1993 AIDS case definition.

² Includes only persons whose date of last contact was within the last 24 months. (01/01/2001-12/31/2002)

Table 4. Other Non-Infectious Conditions¹ Present in \geq 5% of Patients (N=1,526²), 1989-2002

Non-Infectious Condition	N	%
Depression	621	41%
Dermatitis	511	33%
Neuropathy,peripheral	349	23%
Fatigue	333	22%
Hypertension	332	22%
Non-IV drug abuse	297	19%
Drug-related conditions	289	19%
Headache	273	18%
Diarrhea	253	17%
Weight loss,unspecified	238	16%
Weight loss,>10 lbs or 10%	234	15%
Lymphadenopathy	213	14%
Fever	203	13%
Alcohol abuse	196	13%
Pregnancy	192	13%
Nausea	163	11%
Sinusitis	163	11%
Diabetes	151	10%
Night sweats	149	10%
Anxiety	129	8%
Visual disturbances	127	8%
Anergy	98	6%
Nephropathy/renal failure	94	6%
Vomiting	93	6%
Psychosis(inc schizophrenia)	89	6%
Injection drug use	79	5%
Abnormal liver function	76	5%
Thrombocytopenia	73	5%


¹ Includes conditions that are not part of the 1993 AIDS case definition.

² Includes only persons whose date of last contact was within the last 24 months. (01/01/2001-12/31/2002)

Table 5. Primary Malignant Neoplasms, All Patients, 1989-2002 (N=4,612)

Neoplasm Site	Total N	N with CD4 Data	Mean CD4 at Neo. Dx.	Mean Age at Neoplasm Dx.
Anorectal	18	15	295	43
Brain	7	5	55	40
Breast	6	5	216	50
Bone	5	5	182	47
Endocrine	<5	<5	425	35
Esophagus	0			
Genitourinary, Female	47	42	273	34
Genitourinary, Male	9	8	230	54
Heart/mediastinum	0			
Intestine/colon	13	9	369	48
Leukemia	0			
Liver/gall bladder/pancreas	5	<5	135	41
Lymphoma	32	25	129	37
Lung	24	19	144	44
Myeloma	<5	<5	331	40
Oral cavity/pharynx	10	9	143	41
Renal (kidney, bladder)	5	3	482	54
Respiratory, upper	10	8	86	43
Respiratory, lower	<5	<5	246	55
Skin (other than KS)	51	48	245	45
Stomach	<5	<5	186	44
Other	10	8	342	48

Figure 1. Trends in PCP¹, Esophageal Candidiasis¹, Herpes Simplex¹, TB^{1,2}/PTB^{1,3} and Cryptococcosis/Coccidioidomycosis/Histoplasmosis¹, 1990-2002



¹ OIs present at entry into care are excluded. Multiple episodes of OIs are counted. This is a methodological change from the previous report.

² TB: Disseminated or Extrapulmonary TB.

³ PTB: Pulmonary TB.

⁴ The denominator in this figure was changed since the last report from the total number of immunosuppressed persons to all HIV-infected persons in ASD.

Figure 2. Trends in MAC¹, KS¹, Wasting Syndrome¹, CMV¹ and CMV Retinitis¹, 1990-2002





Figure 3. Trends in Dementia², Cryptosporidiosis¹, Toxoplasmosis¹ and Lymphoma², 1990-2002




¹ OIs present at entry into care are excluded. Multiple episodes of OIs are counted. This is a methodological change from the previous report.

² Only first occurrence is counted for patients with more than one episode.

³ The denominator in these figures were changed since the last report from the total number of immunosuppressed persons to all HIV-infected persons in ASD.

Figure 4. Antiretroviral Therapy Regimens Prescribed to ASD Patients, 1995-2002



¹ HAART regimen is defined as

a) ≥ 3 drugs including a protease inhibitor (PI).


b) ≥ 3 drugs including a non-nucleoside reverse transcriptase inhibitor (NNRTI)

c) 3 drugs including nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) that includes abacavir or tenofovir.

² Other antiretroviral therapy includes other combinations which do not qualify as a HAART regimen.

³ No antiretroviral therapy regimen prescribed.

Figure 5. Mortality Rate (per 100 Person-Years) for HIV-Infected Persons Enrolled in ASD, 1990-2002



* 2002 data are not complete due to delays in reporting.

Figure 6. Health Service Utilization (per person per year) by Range of Lowest CD4, 1990-2002

Rate of Outpatient Visits





Figure 7. Rate of Emergency Room Visits



¹ Total includes patients without a CD4 Count..

Figure 8. Health Service Utilization (per person per year) by Range of Lowest CD4, 1990-2002

Rate of Hospitalizations





Figure 9. Rate of Hospital Days



¹ Total includes patients without a CD4 Count..

Figure 10. Lowest CD4 Count among ASD Patients in a Given Year, 1990-2002





Figure 11. Highest Viral Load among ASD Patients in a Given Year, 1996-2002



ASD Bibliography

(CDC-authored publications and abstracts are indicated by bold-faced type. Copies of these are available from the Surveillance Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd., Mail stop E-46.)

Peer-Reviewed Publications

1992

1. Braun J, Bryan E, Evans R, Friedland G, Greenberg A, Holzman R, Landesman S, Mildvan D, Sieldlin M, Starrett, B, Thomas P. The spectrum of HIV-1 related disease among outpatients in New York City. *AIDS*. 1992; 6(8):849-59.
2. **Farizo K, Kelly J, Buehler J, Whyte B, Mokotoff E, Bell C, Brandon W, Nahlen B, Phelps A, Stephens J, Davidson A, Minkoff H. Provision of gynecologic care at outpatient medical facilities serving HIV-Infected persons. *J Women's Health*. 1992; 1:193-196.**
3. **Farizo K, Buehler J, Chamberland M, Whyte B, Froelicher E, Hopkins S, Reed C, Mokotoff E, Cohn D, Troxler S, Phelps A, Berkelman R. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. *JAMA*. 1992; 267; 13:1798-1805.**

1993

1. Brandon W, Boulos L, and Morse A. Determining the prevalence of neurosyphilis in a cohort co-infected with HIV. *Internatl J STD & AIDS*. 1993; 4:99-101.
2. Rietmeijer C. The cost of acquired immunodeficiency syndrome and human immunodeficiency virus infection: the experience of a public hospital in the context of national forecasts. *Comprehensive Therapy*. 1993; 19:174-176.
3. Rietmeijer C, Davidson A, and Foster C, Cohn D. Cost of care for patients with HIV infection: patterns of utilization and charges in a public health care system. *Arch Intern Med*. 1993; 153:219-225.

1994

1. **Jones J, Hanson D, Chu S, Fleming P, Hu D, Ward J, Adult/Adolescent Spectrum of HIV Disease Project Group. Surveillance of AIDS-defining conditions in the United States. *AIDS*. 1994; 8:1489-1493.**
2. Wortley P, Chu S, Blostein J, Farley T, Morrison L, Kovacs A, Thompson S. Care of pregnant women infected with HIV. *JAMA*. 1994; 271; 4:271-272.

3. **Wortley P, Farizo F, Adult and Adolescent Spectrum of HIV Disease Project Group. Pneumococcal and influenza vaccination levels among HIV-infected adolescents and adults receiving medical care in the United States. *AIDS*. 1994; 8:941-944.**

1995

1. **Buchbinder S, Conley L, Hershov Ronald, Holmberg S, Judson F, Katz M, Penley K, Wong L. The spectrum of medical conditions and symptoms before Acquired Immunodeficiency Virus. *American Journal of Epidemiology*. 1995; 141(5):395-404.**
2. **Chu S, Hanson D, Ciesielski C, Ward J. Prophylaxis against *Pneumocystis carinii* pneumonia at higher CD4+ T cell counts. *JAMA*. 1995; 155:1537-1542.**
3. **Hanson D, Chu S, Farizo K, Ward J, Adult and Adolescent Spectrum of HIV Disease Project Group. Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. *Arch Intern Med*. 1995; 155:1537-1542.**
4. **Jones J, Hanson D, Chu S, Ward J, Jaffe H. AIDS-associated Kaposi's sarcoma. *Science*. 1995; 267:1078-9.**
5. **Kaplan J, Masur H, Holmes K, McNeil M, Schonberger L, Navin T, Hanson D, Gross P, Jaffe H. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Introduction. *CID*. 1995; 21:(Suppl 1):S1-S11.**
6. Kissinger P, Cohen D, Brandon W, Rice J, Morse A, Clark R. Compliance with public sector HIV medical care. *J Natl Med Assoc*. 1995;87:19-24.
7. Kissinger P, Clark R, Morse A, Brandon W. Comparison of multiple drug therapy regimens for HIV-related disseminated *Mycobacterium avium* complex disease. *J Acquir Immune Defic Syndr & Human Retrovirol*. 1995;9:133-137.
8. Sorvillo F, Kerndt P, Chen K-J, Beall G, Turner P, Beer V, Kovacs A. Emerging patterns of HIV transmission: the value of alternative surveillance methods. *AIDS*. 1995;9:625-629.
9. Sorvillo F, Nahlen B. Influenza immunization for HIV-infected persons in Los Angeles. *Vaccine*. 1995;13:377-380.

1996

1. Belafsky P, Clark R, Kissinger P, Torres J. Natural history of low-grade squamous intraepithelial lesions in women infected with human immunodeficiency virus. [Letter]. *J Acquir Immune Defic Syndr Human Retrovirol*. 1996;11:511-512.

Updated February 6, 2003

2. Clark R, Kissinger P, Fuller C, Abdalian S. Squamous intraepithelial lesions among adolescent women infected with human immunodeficiency virus. [Letter]. *J Adolesc Health*. 1996;19:246-247.
3. Clark R, Kissinger P, Williams T. Contraception and sexually transmitted diseases protection among HIV infected women and female adolescents. *Internatl J STD & AIDS*. 1996;7:439-442.
4. **Chu S, Hanson D, Jones J, Adult and Adolescent Spectrum of HIV Disease Project Group. Pregnancy rates among women infected with human immunodeficiency virus. *Obstet & Gynecol*. 1996;87:195-198.**
5. Fuller C, Clark R, Kissinger P, Abdalian S. Clinical manifestations of infection with human immunodeficiency virus among adolescents in Louisiana. *J Adolesc Health*. 1996;18:422-428.
6. **Horsburgh C, Hanson D, Jones J, Thompson S. Protection from *Mycobacterium avium* complex disease in human immunodeficiency virus-infected persons with a history of tuberculosis. *J Infect Dis*. 1996;174:1212-1217.**
7. **Jones J, Hanson D, Chu S, Ciesielski C, Kaplan J, Ward J, Navin T, Adult and Adolescent Spectrum of HIV Disease Group. Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends. *AIDS*. 1996;10:1393-1399.**
8. Kissinger P, Clark R, Dumestre J, Bessinger R. Incidence of three sexually transmitted diseases during a safer sex promotion program for HIV-infected women. *J Gen Intern Med*. 1996;11:750-752.

1997

1. Belafsky P, Kissinger P, Clark R, Moore B. The association between sinusitis and survival among individuals infected with human immunodeficiency virus. *Journal of Rhinology*.
2. Bessinger R, Beilke M, Kissinger P, Jarrot C, Tabak F. Retroviral coinfections at a New Orleans HIV outpatient clinic. *J Acquir Immune Defic Syndr Human Retrovirol*. 1997;14:67-71.
3. Clark R, Bessinger R. Cryptosporidiosis among patients infected with human immunodeficiency virus: factors related to symptomatic infection and survival. [Letter]. *Am J Epidemiol*. 1997;146:358-359.
4. Fernandez D, Gomez M, Hunter R, Minino A, Velazquez M. Psychological behavioral issues of a cohort of Puerto Rican HIV/AIDS patients. *Cellular and Microbiology*. 1997;43(7):1115-1122.
5. Gomez M, Velazquez M, and Hunter R. Outline of the Human Retrovirus Registry: profile of a Puerto Rican HIV infected population. *Bol Assoc Med Puerto Rico*. 1997;89:111-116.

6. **Karon J, Green T, Hanson D, Ward J. Estimating the number of AIDS-defining opportunistic illness diagnoses from data collected under the 1993 AIDS surveillance definition. *J Acquir Immune Defic Syndr Human Retrovirol.* 1997;16:116-121.**
7. Kissinger P, Fuller C, Clark R, Abdalian S. Psychosocial characteristics of HIV-infected adolescents in New Orleans. [Letter]. *J Adolesc Health.* 1997;20:258.
8. Minino A, Gomez M, Velazquez M, Hunter R. Gender-related differences in the spectrum of HIV disease in the Bayamon area, Puerto Rico. *Cell Mol Biol.* 1997;43:1139-1143.
9. Rivera del Rio J, Flores R, Melendez J, Gomez M, Vila S, Hunter R. Profile of patients with and without bacterial endocarditis. *Cell Mol Biol.* 1997;43:1153-1160.
10. **Serrano M, Smith N, Shandera W. Epidemiology of human immunodeficiency virus infection in Central Americans treated in Harris County, Texas Hospital District facilities. *Am J Trop Med Hygiene.* 1997;57:678-682.**
11. Sorvillo F, Beall G, Turner P, Beer V, Kovacs A, Kerndt P. Incidence and factors associated with extrapulmonary *Cryptococcus* among persons with HIV infection in Los Angeles County. *AIDS.* 1997;11:673-679.
12. **Sullivan P, et al. Published erratum appears for reference 13 in *J Acquir Immune Defic Syndr Hum Retrovirol.* 1997;15:94.**
13. **Sullivan P, Hanson D, Chu S, Jones J, Ciesielski C, Adult/Adolescent Spectrum of Disease Group. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate adult and adolescent spectrum of disease project. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1997;14:374-379.**

1998

1. Bedimo A, Bessinger R, Kissinger P. Reproductive choices among HIV-infected women. *Social Sciences and Medicine.* 1998;46:171-179.
2. Bessinger R, Clark R, Kissinger P, Rice, J, Coughlin S. Pregnancy is not associated with an increase in progression of HIV disease in women attending an outpatient program. *Am J Epidemiol.* 1998;147:434-440.
3. Buskin S, Diamond C, Hopkins S. HIV-Infected pregnant women and progression of HIV disease. [Letter]. *Arch Intern Med.* 1998;158:1277-1278.
4. Buskin S, Diamond C, Hopkins S. Lack of an epidemiologic link between Kaposi's sarcoma and central nervous system lymphoma in persons with AIDS. *Neurology.* 1998;51(5):1513.

5. Clark R, Kissinger P, Michaels S. Declining morbidity and mortality among patients with advanced Human Immunodeficiency Virus Infection. *The New England Journal of Medicine*. 1998;339 (6):406.
6. Diamond C, Buskin S. Continued risk behavior in HIV-infected youth. *Am J Epidemiol*. 1998;147:S61.
7. Gordon C, Inguanga J, Morse A. Neurosyphilis during the AIDS epidemic, New Orleans, 1990-1997. *Journal Infectious Diseases*. 1998;178:1229.
8. **Jones J, Hanson D, Dworkin M, Kaplan J, Ward J, Adult/Adolescent Spectrum of Disease Group. Trends in AIDS-related opportunistic illnesses among men who have sex with men and among injecting drug users, 1991-1996. *J Infect Dis*. 1998;178:114-120.**
9. **Kaplan J, Hanson D, Navin T, Jones J. Risk factors for primary *Pneumocystis carinii* pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: Reassessment of indications for chemoprophylaxis. *J Infect Dis*. 1998;178:1126-1132.**
10. **Lansky A, Jones J, Wan P-CT, Lindegren M, Wortley P. Trends in zidovudine prescription for pregnant women infected with HIV. *J Acquir Immun Def Syndr Hum Retrovirol*. 1998;18:289-292.**
11. **Lansky A, Ward J, Jones J. Combination antiretroviral therapy for HIV infection: policies and practices. [Letter]. *AIDS*. 1998;12:1552-1553.**
12. **Qureshi A, Hanson D, Jones J, Janssen R. Estimation of the temporal probability of human immunodeficiency virus (HIV) dementia after risk stratification for HIV-infected persons. *Neurology*. 1998;50:392-397.**
13. Sorvillo F, Beall G, Turner P, Beer V, Kovacs A, Kraus P, Masters D, Kerndt P. Seasonality and factors associated with cryptosporidiosis among individuals with HIV infection. *Epidemiol & Infect*. 1998;121:197-204.
14. Sorvillo F, Kovacs A, Kerndt P, Stek A, Muderspach L, Sanchez-Keeland L. Risk factors for trichomoniasis among women with HIV infection at a public clinic in Los Angeles County: implications for HIV prevention. *Am J Trop Med Hygiene*. 1998;54:495-500.
15. **Sullivan P, Hanson D, Chu S, Jones J, Ward J. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. *Blood*. 1998;91:301-308.**
16. Welch K, Kissinger P, Bessinger R, Dascomb K, Morse A, Gleckler E. The clinical profile of end-stage AIDS. *AIDS Patient Care*. 1998;12(2):125-129.

1999

Updated February 6, 2003

1. Buskin S, Newcomer L, Koutsky L, Hooton T, Spach D, Hopkins S. The effect of trimethoprim-sulfamethoxazole as *Pneumocystis carinii* pneumonia prophylaxis on bacterial illness, *Pneumocystis carinii* pneumonia, and death in persons with AIDS. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1999;20:201-206.
2. **Dworkin M, Sullivan P, Buskin S, Harrington R, Olliffe J, MacArthur R, Lopez C. *Bordetella bronchiseptica* infection in human immunodeficiency virus-infected patients. *Clin Infect Dis.* 1999;28:1095-1099.**
3. **Dworkin M, Wan P, Hanson D, Jones J. Progressive multifocal leukoencephalopathy: Improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. *Journ Infect Dis.* 1999;180:621-5.**
4. Guerrero M, Kruger S, Saitoh A, Sorvillo F, Cheng KJ, French C, Beall G. Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention. *AIDS.* 1999;13:1971-1975.
5. **Jones J, Hanson D, Dworkin M, Ward J, Jaffe H. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. *J Acquir Immune Defic Syndr.* 1999;21:S11-S17.**
6. **Jones J, Hanson D, Dworkin M, Alderton D, Fleming P, Kaplan J, Ward J. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. *Morbidity Mortality Weekly Report MMWR.* 1999;48(No. SS-2):1-22.**
7. Kopicko J, Momodu I, Adedokun A, Hoffman M, Clark R, Kissinger P. Characteristics of HIV-infected men with low serum testosterone levels. *International Journal of STD & AIDS.* 1999;10:817-820.
8. **Lansky A, Jones J, Burkham S, Reynolds K, Bohannon B, Bertolli J. Adequacy of prenatal care and prescription of zidovudine to prevent perinatal HIV transmission. *J Acquir Immune Defic Syndr.* 1999;21:223-227.**
9. **McNaghten A, Hanson D, Jones J, Dworkin M, Ward J, the Adult and Adolescent Spectrum of HIV Disease Project. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. *AIDS.* 1999; 13:1687-95.**
10. Michaels S, Clark R, Kissinger P. Incidence and spectrum of AIDS-defining illnesses among persons treated with antiretroviral drugs. *Clin Infect Dis.* 1999;29:468-469.

2000

1. Diamond C, Buskin S. Continued Risky Behavior in HIV-Infected Youth. *Am J Pub Hlth.* 2000;90:115-118.
2. **Dworkin M, Hanson D, Kaplan J, Jones J, Ward J, and the Adult and Adolescent Spectrum of HIV Disease Project. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. *J Infect Dis.* 2000;182:611-615.**
3. **Dworkin M, et al. Patient-focused antiretroviral therapy. [Letter]. *Ann Intern Med.***
4. **Dworkin M, Hanson D. Epidemiologic relation between HIV and invasive Pneumococcal disease in San Francisco County, California [Letter]. *Ann Intern Med.* 2000; 132:1009.**
5. **Dworkin M, Wan P-C, the ASD Project. Surveillance of antiretroviral prescriptions [Letter]. *JAIDS.* 2000;24(3):294.**
6. Gomez M, Fernandez D, Otero J, Miranda S, Hunter R. The Shape of the HIV/AIDS epidemic in Puerto Rico. *PAHO Journal.* 2000; 7(6):377-383.
7. **Holding K, Dworkin M, Wan P-C, Hanson D, Klevens R, Jones J, Sullivan P, the Adult and Adolescent Spectrum of HIV Disease Project. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. *Clin Infect Dis.* 2000;31:1253-1257.**
8. Inungu J, Morse A, Gordon C. Risk factors, seasonality, and trends of cryptosporidiosis among HIV-infected patients. *Am Journ Trop Med & Hyg.* 2000;62:384-387.
9. **Jones J, Hanson D, Dworkin M, Jaffe H, ASD Project Group. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2000;24:270-274**
10. **Jones J, Hanson D, Dworkin M, DeCock K, and the Adult/Adolescent Spectrum of HIV Disease Group. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. *Internat J Tuberculosis & Lung Dis.* 2000;4:1026-1031.**
11. **Kaplan J, Hanson D, Dworkin M, Frederick T, Bertolli J, Lindegren M, Holmberg S, Jones J. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. *Clin Infect Dis.* 2000;30(Suppl. 1):S5-S14.**
12. **Lowther S, Dworkin M, Hanson D, the Adult and Adolescent Spectrum of HIV Disease Project. *Entamoeba histolytica/Entamoeba dispar* infections in human immunodeficiency virus-infected patients in the United States. *Clin Infect Dis.* 2000; 30:955-959.**
13. Lundberg B, Davidson A, Burman W. Epidemiology of *Pneumocystis carinii* pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. *AIDS.* 2000;14:2559-2566.

Updated February 6, 2003

14. McCarthy W, Gable J, Lawrence J, Rimland D, Thompson M. A retrospective study to determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV-1 infected individuals. *Pharmacoepepi & Drug Safety*. 2000;9:49-53.
15. **McCombs S, Dworkin M, Wan P-C, the Adult and Adolescent Spectrum of HIV Disease Project Group. Helminth infections in HIV-infected persons in the United States, 1990-1999. *Clin Infect Dis*. 2000;30:241-242.**
16. Niccolai L, Kopicko J, Kassie A, Petros H, Clark R, Kissinger P. Incidence and predictors of reinfection with *Trichomonas vaginalis* in HIV-infected women. *Sex Trans Dis*. 2000;27:284-288.
17. Sackoff J, McFarland J, Shin S. Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics. *J Acquir Immune Defic Syndr*. 2000;23:178-183.
18. **Sullivan P, Hanson D, Dworkin M, Jones J, Ward J, the Adult and Adolescent Spectrum of HIV Disease Investigators. Effect of influenza vaccination on disease progression among HIV-infected persons. *AIDS*. 2000;14:2781-2785.**
19. **Sullivan P, Dworkin M, Jones J, Hooper W, the Adult and Adolescent Spectrum of HIV Disease Project. Epidemiology of thrombosis in HIV-infected individuals. *AIDS*. 2000;14:321-324.**
20. Welch K, Morse A, Clark R, Ogbuokiri T. Factors associated with incomplete virological response to highly active antiretroviral therapy. *Clin Infect Dis*. 2000;30(2):407-8.

2001

1. Butt A, Dascomb K, DeSalvo K, Bazzano L, Kissinger P, Szerlip H, mention of the ASD database. Human immunodeficiency virus infection in elderly patients. *Southern Medical Journal*. 2001;94(4):397-400.
2. Diamond C, Davidson A, Sorvillo F, Buskin S. HIV-Infected American Indians/Alaska Natives in the Western United States. *Eth Dis*. 2001; 11:633-644.
3. **Do A, Hanson D, Dworkin M, Jones J, the Adult and Adolescent Spectrum of HIV Disease Project. Risk factors for and trends in gonorrhoea incidence among persons infected with HIV in the United States. *AIDS* 2001 June;15(9):1149-1155.**
4. **Dworkin M, Williamson J, Jones J, Kaplan J, the Adult and Adolescent Spectrum of HIV Disease Project. Prophylaxis with trimethoprim-sulfamethoxazole for human**

immunodeficiency virus-infected patients: impact on risk for infectious diseases. *Clin Infect Diseases* 2001;33:393-398.

5. **Dworkin M, Wan P. Indinavir, Zidovudine, Lamivudine: 3 year follow-up. *Ann Intern Med.* 2001;134:165.**
6. **Dworkin M, Hanson D, Navin T, the Adult and Adolescent Spectrum of HIV Disease Project. Survival of patients with AIDS after diagnosis of *Pneumocystis carinii* pneumonia in the United States. *Journal of Infectious Diseases.* 2001;183:1409-1412.**
7. Dworkin M, Ward John, Hanson D, Jones J, Kaplan J, Adult Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence and risk factors and impact of vaccination. *Clinical Infectious Diseases* 2001:794-800.
8. Fernandez D, Gomez M, Gomez O, Mayor A, Hunter R. Survival of AIDS patients according to injecting drug use in Puerto Rican AIDS patients. *Cellular and Molecular Biology.* 2001;47(7):1121-1127.
9. Kaplan J, Hanson D, Jones J, Dworkin M, the Adult and Adolescent Spectrum of HIV Disease Project. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. *AIDS.* 2001; 15:1831-1836.
10. Mayor A, Gomez M, Otero J, Vila S, Hunter R. Pulmonary tuberculosis mortality risks in a cohort of injecting drug use in Puerto Rican AIDS patients. *Cellular and Molecular Biology.* 2001;47(7):1143-1148.
11. **McNaghten A, Adams M, Dworkin M, the Adult and Adolescent Spectrum of HIV Disease Project Group. Case 23-2000: Osteomyelitis in HIV-infected patients. *N Engl J Med.* 2001;344:66-67.**
12. McNaghten A, Wan P, Dworkin M, the Adult and Adolescent Spectrum of HIV Disease Project Group. Prevalence of hearing loss in a cohort of HIV-infected individuals. *JAMA Otolaryngology – Head and Neck surgery.* 2001;127:1516-1518.
13. Peredo R, Sastre G, Serrano J, Hunter Mellado R. HER-2/NEU Oncogene expression in Puerto Rican females with breast cancer. *Cellular and Molecular Biology.* 2001;47(6):1025-1032.
14. Reiss G, O'Brien M, Kopicko J, Clark R. Lack of association between pregnancy and selected gastrointestinal adverse events among women prescribed nelfinavir [Letter]. *JAIDS.* 2001 April; 26:513-514.
15. Sackoff J, Bernard M, Adams L. [Letter]. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. *Int J Tuberc Lung Dis.* 2001 May; 5(5): 489.

16. Sorvillo F, Beall G, Turner P, Beer V, Kovacs A, Kerndt P. Incidence and determinants of *Pseudomonas aeruginosa* infection among persons with HIV: association with hospital exposure. *Am J Infect Control*. 2001 April; 29(2):79-84.
17. Welch K, Morse A. Survival patterns among HIV+ individuals based on health care utilization. *J Natl Med Assoc*. 2001 June; 93:214-219.
18. Wohl A, Lu S, Rollins J, Simon P, Grosser S, Kerndt P. Comparison of AIDS progression and survival in persons with pulmonary versus extrapulmonary tuberculosis in Los Angeles. *AIDS Pat Care STD*. 2001; 15(9): 463-471.

2002

1. Montgomery J, Gillespie B, Gentry A, Mokotoff E, Crane L, James S. Does access to health care impact survival time after diagnosis of AIDS? *AIDS Pat Care STD*. 2002; 16(5):223-231.
2. Welch K, Morse A, the Adult and Adolescent Spectrum of HIV Disease. Association between efavirenz and selected psychiatric and neurological conditions. *JID*. 2002 January; 185:267-268.
3. Welch K, Morse A, the Adult and Adolescent Spectrum of Disease Project in New Orleans. The clinical profile of end-stage AIDS in the era of highly active antiretroviral therapy. *AIDS Patient Care and STDs*. 2002 February; 16:75-81.
4. Welch K, Morse A, the Adult and Adolescent Spectrum of Disease Project in New Orleans. Improving screening and vaccination for hepatitis B in patients co-infected with HIV and hepatitis C. *The American Journal of Gastroenterology*. 2002 November; 97(11):2928-9.
5. Welch K, Morse A, the Adult and Adolescent Spectrum of Disease Project in New Orleans. Improving tuberculin skin testing in HIV-infected individuals. *The American Journal of Respiratory and Critical Care Medicine*. 2002 July; 165(10):1452.
6. Welch K, Morse A, the Adult and Adolescent Spectrum of HIV Disease. Predictors of survival in older men with AIDS. *Journal of Geriatric Nursing*. 2002;23:62-68.

2003

1. Johnson D, Sorvillo F, Wohl A, Bunch G, Harawa N, Carruth A, Castillon M, Jimenez B. Frequent Failed Early HIV Detection in a High Prevalence Area: Implications for Prevention. *AIDS Pat Care STD*. 2003; 17(6):277-282.
2. Wohl AR, Lu S, Turner J, Kovacs A, Witt M, Squires K, Towner W, Beer V. Risk of Opportunistic Infection in the HAART Era Among HIV-Infected Latinos Born in the United

Updated February 6, 2003

States Compared to Latinos Born in Mexico and Central America. *AIDS Pat Care STD*. 2003; 17(6):267-275.

3. Kellerman S, Hanson D, McNaghten AD, Fleming P. Prevalence of Chronic Hepatitis B and Incidence of Acute Hepatitis B Infection in Human Immunodeficiency Virus–Infected Subjects · The Journal of Infectious Diseases 2003;188:571-577.
4. **Kaplan JE, Hanson DL, Cohn DL, Karon J, Buskin S, Thompson M, Fleming P, Dworkin MS; Adult and Adolescent Spectrum of HIV Disease Project Investigators. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL. Clin Infect Dis. 2003 Oct 1;37(7):951-8. Epub 2003 Sep 12.**

Abstracts and Presentations

1990

Buskin S, Hopkins S, Chamberland M. 1990. Spectrum of HIV-related diseases and conditions among outpatients. VI International Conference on AIDS, San Francisco, California.

1991

Buskin S, Hopkins S, Sohlberg E, Ward J, Farizo K. 1991. Are HIV-infected persons receiving care at an emergency facility different from those using other outpatient sites? VII International Conference on AIDS, Florence, Italy.

Reynolds K, Phelps A. 1991. Changing faces of HIV infected individuals presenting for care at a publicly funded health care facility. Presentation at the 119th Annual Meeting and Exhibit of the American Public Health Association, Atlanta, Georgia.

Rietmeijer C, Davidson A, Cohn D. 1991. Cost of care in HIV infection: evaluation of utilization and charges in a public hospital. VII International Conference on AIDS, Florence, Italy.

Thompson M, Whyte B, Morris A, Rimland D, Thompson S. 1991. Gender differences in the spectrum on HIV disease. VII International Conference on AIDS, Florence, Italy.

Ward J, Hopkins S, Buskin S, Sohlberg E, Farizo K. 1991. HIV-related prophylaxis and the rate of progression to AIDS among HIV-infected persons, Seattle, Washington, USA. VII International Conference on AIDS, Florence, Italy.

1992

Brandon W, Boulos L, Morse A. 1992. The natural history of neurosyphilis in a cohort co-infected with HIV. VIII International Conference on AIDS, Amsterdam, The Netherlands.

Buskin S, Hopkins S, Farizo K. 1992. Heavy smoking increases the risk of *Pneumocystis carinii* pneumonia. VIII International Conference on AIDS, Amsterdam, The Netherlands.

Buskin S, Maden C, Sohlberg E, Hopkins S. 1992. Smoking and the risk of AIDS, *Pneumocystis carinii* pneumonia, esophageal candidiasis, and death in HIV-1 seropositive persons. VIII International Conference on AIDS, Amsterdam, The Netherlands.

Cohn D, Rietmeijer C, St. John M-A, Paulson A, Hagglund B, Davidson A. 1992. Impact of the revised CDC classification system of HIV infection, Denver, 1990-1991. VIII International Conference on AIDS, Amsterdam, The Netherlands.

Creagh T, Thompson M, Morris A, ARCA Spectrum of Disease Working Group, Whyte B. 1992. Gender differences in the spectrum of HIV disease. VIII International Conference on AIDS, Amsterdam, The Netherlands.

Davidson A, Rietmeijer C, Hagglund B, Paulson A, St. John M-A, Cohn D. 1992. Relation of social factors to health care utilization and health status assessment in HIV-infected patients. VIII International Conference on AIDS, Amsterdam, The Netherlands.

Inungu N, Boulos L, Morse A, Boulos M, Stansbury E, Brandon W, Troxler S. 1992. Disseminated Mycobacterium infection among HIV positive patients at the Medical Center of Louisiana in New Orleans. VIII International Conference on AIDS, Amsterdam, The Netherlands.

Morse A, Brandon W, Boulos L. 1992. Determining the natural history of syphilis in a cohort of 246 patients co-infected with HIV. VIII International Conference on AIDS, Amsterdam, The Netherlands.

Nahlen B, Sorvillo F, Farizo K. 1992. Anemia among adults with HIV infection in Los Angeles County. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California.

Nahlen B, Sorvillo F, Farizo K. 1992. Seroprevalence of toxoplasmosis among HIV-infected adults in Los Angeles, California. VIII International Conference on AIDS, Amsterdam, The Netherlands.

Pfeffer G, Morse A, Brandon W, Troxler S, Stansbury E, Kissinger P. 1992. Care utilization in HIV patients at the Medical Center of Louisiana, New Orleans. VIII International Conference on AIDS, Amsterdam, The Netherlands.

Sorvillo F, Nahlen B, Farizo K. 1992. Utilization of influenza vaccine among persons with HIV in Los Angeles County. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California.

Thompson M, Creagh T, Morris A, ARCA Spectrum of Disease Working Group, Whyte B. 1992. Risk factors for CMV disease in patients with HIV infection. VIII International Conference on AIDS, Amsterdam, The Netherlands.

1993

Creagh T, Thompson M, Morris A, Thompson S, Rimland D, Whyte B. 1993. Gender differences in the spectrum of HIV disease in Georgia. IX International Conference on AIDS, Berlin, Germany.

Morris A, Creagh T, Thompson M, ARCA Spectrum of Disease Working Group, Toomey K. 1993. Impact of CDC's new AIDS definition in metropolitan Atlanta. IX International Conference on AIDS, Berlin, Germany.

Updated February 6, 2003

Morse A, Kissinger P, Clark R, Brandon W. 1993. Prevalence of AIDS indicator diseases in a deceased HIV cohort in New Orleans. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana.

Thompson M, Creagh T, Morris A, ARCA Spectrum of Disease Working Group, Toomey K. 1993. Impact of antiretroviral therapy on survival and CD4+ decline in Georgia. IX International Conference on AIDS, Berlin, Germany.

1994

Caraballo R, Orengo J, Hunter R, Rios E, Velazquez M, Cruz A, Gomez M. 1994. Comparison of T-Helper cells, T-Suppressor cells and absolute lymphocyte counts by vulnerability group: the UCCEM/HURRA Study. Research Centers for Minority Institutions AIDS International Symposium, San Juan, Puerto Rico.

Gomez M, Ramirez H, Hunter R, Velazquez M. 1994. Preliminary results on the study of survival in a Puerto Rican HIV/AIDS population. Research Centers for Minority Institutions AIDS International Symposium, San Juan, Puerto Rico.

Gomez M, Velazquez M, Ramirez H, Hunter R. 1994. Persistent risk behaviors in a Puerto Rican HIV/AIDS population. Research Centers for Minority Institutions AIDS International Symposium, San Juan, Puerto Rico.

Greene V, Chu S, Hanson D, Cleveland J, Adult/Adolescent Spectrum of Disease Project Group. 1994. Update on clinical factors related to thrush in HIV-infected persons. Presentation at the 122nd Annual Meeting and Exhibit of the American Public Health Association, Washington, DC.

Hunter R, Velazquez M, Rios E, Ramirez H, Gomez M. 1994. Gender and HIV disease in female Hispanics. Research Centers for Minority Institutions AIDS International Symposium, San Juan, Puerto Rico.

Orengo J, Gomez M, Hunter R. 1994. Profile of diseases of AIDS cases with TB vs AIDS cases without TB in Bayamon, Puerto Rico. Research Centers for Minority Institutions AIDS International Symposium, San Juan, Puerto Rico.

Rivera Del Rio J, Montilla J, Ramirez H, Gomez M, Hunter R. 1994. Echocardiographic evaluation in AIDS. Research Centers for Minority Institutions AIDS International Symposium, San Juan, Puerto Rico.

Santiago A, Hunter R, Gomez M, Martinez S. 1994. The adult spectrum of disease (ASD) in Bayamon, Puerto Rico. Research Centers for Minority Institutions AIDS International Symposium, San Juan, Puerto Rico.

Thompson M, Creagh T, Harmon M, Rimland D, Thompson S, Toomey K. 1994. Impact of AZT monotherapy versus sequential or combination antiretroviral therapy on survival. X International Conference on AIDS, Yokohama, Japan.

1995

Gomez M, Fernandez D, Velazquez M, Hunter R. 1995. Sociodemographic, risk and clinical factors associated with depression among a cohort of Puerto Rican HIV/AIDS patients. Presentation at the 123rd Annual Meeting and Exhibit of the American Public Health Association, Indianapolis, Indiana.

Hunter R. 1995. Moving trends of the HIV epidemics in Puerto Rico, AIDS International Day, Universidad Central del Caribe, University Hospital Dr. Ramon Ruiz Arnau, Bayamon, Puerto Rico.

Styrt B, Cvetkovich T. 1995. Thrombotic microangiopathies in human immunodeficiency virus infection. Infectious Diseases Society of America 33rd Annual Meeting, Orlando, Florida.

Sullivan P, Chu S, Jones J, Hanson D, Ward J. 1995. Epidemiology of hematologic manifestations of HIV infection. American Society of Hematology Meeting, Seattle, Washington.

Ward J, Hanson D, Chu S, Jones J. 1995. Survival and trends in anti-retroviral therapy and anti-microbial prophylaxis among persons with 1993-defined AIDS. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California.

1996

Al-Qasbi A, Kissinger P, Morse A, Clark R. 1996. Patterns of opportunistic infection among HIV-infected persons. Infectious Diseases Society of America 34th Annual Meeting, New Orleans, Louisiana.

Bach J, Clark R, Kissinger P, Pindaro C. 1996. Renal disease in women infected with HIV. XI International Conference on AIDS, Vancouver, British Columbia.

Bangdiwala S, Hunter R, Gomez M. 1996. Factors related to HIV+ versus AIDS presentation at the first contact with health services. Fifth NIH Research Centers for Minority Institutions AIDS International Symposium, Rio Grande, Puerto Rico.

Buskin S, Thiede H, Hopkins S. 1996. High risk behaviors in HIV-infected persons. XI International Conference on AIDS, Vancouver, British Columbia.

Clark R, Bessinger R, Kissinger P, Thomas C. 1996 Experience with megestrol acetate for treatment of HIV-related cachexia in women. XI International Conference on AIDS, Vancouver, British Columbia.

Clark R, Kissinger P, Bessinger R, Thomas C. 1996. Does megestrol acetate improve survival in patient with AIDS related wasting? Infectious Diseases Society of America 34th Annual Meeting, New Orleans, Louisiana.

Updated February 6, 2003

Creagh T, Thompson M, Harmon M, Rimland D, Lennox J, Toomey K. 1996. Survival in HIV-infected women in Atlanta. The Third Conference on Retroviruses and Opportunistic Infections, Washington, DC.

Duchin J, Sohlberg E, Buskin S, Hopkins S, Simon P. 1996. Risk factors for *Pneumocystis carinii* pneumonia: delayed diagnosis of HIV infection and failure to receive prophylactic therapy. XI International Conference on AIDS, Vancouver, British Columbia.

Fernandez-Santos D, Gomez M, Hunter R. 1996. Psychological and behavioral issues of a cohort of Puerto Rican HIV/AIDS patients. Fifth NIH Research Centers for Minority Institutions AIDS International Symposium, Rio Grande, Puerto Rico.

Gomez M, Fernandez D, Velazquez M, Hunter R. 1996. HIV/AIDS in a Puerto Rican adolescent and young women population: psychological and risk related features. NIH Research Centers for Minority Institutions AIDS International Symposium, Rio Grande, Puerto Rico.

Hunter R, Gomez M. 1996. Age and the expression of HIV in Puerto Rico. NIH Research Centers for Minority Institutions AIDS International Symposium, Rio Grande, Puerto Rico.

Hunter R, Negron J, Rios E, Vila S, Gomez M. 1996. Moving trends of the HIV epidemic in the Bayamon health region: spectrum of patients requiring hospitalization between 1992-1995. NIH Research Centers for Minority Institutions AIDS International Symposium, Rio Grande, Puerto Rico.

Hunter R, Velazquez M, Vila S, Cancel L, Gomez M. 1996. Age and the expression of HIV in Puerto Rico. The Third Conference on Retroviruses and Opportunistic Infections, Washington, DC.

Hunter R, Velazquez M, Vila S, Rios E, Gomez M. 1996. Changing trends in the clinical spectrum of hospital HIV+ patients in the last three years. The Third Conference on Retroviruses and Opportunistic Infections, Washington, DC.

Jones J, Hanson D, Kaplan J, Ward J. 1996. Decreases in *Pneumocystis carinii* pneumonia incidence and fatality. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana.

Jones J, Hanson D, Ward J, Kaplan J. 1996. Incidence trends in AIDS-related opportunistic illnesses in injecting drug users and men who have sex with men. XI International Conference on AIDS, Vancouver, British Columbia.

Kaplan J, Jones J, Hanson D, Ward J. 1996. Risk factors for death from *Pneumocystis carinii* pneumonia in the United States. XI International Conference on AIDS, Vancouver, British Columbia.

Minino A, Hunter R, Gomez M. 1996. Gender related differences in the spectrum of HIV disease in the Bayamon area, Puerto Rico. Fifth NIH Research Centers for Minority Institutions AIDS International Symposium, Rio Grande, Puerto Rico.

Pagan-Santini R, Gomez M, Rios E, Hunter R. 1996. Psychological and behavioral profile of men who have sex with men with HIV/AIDS in the Bayamon region of Puerto Rico. Fifth NIH Research Centers for Minority Institutions AIDS International Symposium, Rio Grande, Puerto Rico.

Pearce K, Haefner H, Kissinger P, Roboussin D, Nolan T. 1996. HIV infection and risk of abnormal cytopathology after hysterectomy for benign disease. American College of Obstetrics and Gynecology.

Rietmeijer C, Davidson A, Cohn D. 1996. Decreasing cost for HIV-related medical services associated with shorter hospital stays in a public health care system. XI International Conference on AIDS, Vancouver, British Columbia.

Rios E, Gomez M, Minino A, Vila S, Hunter R. 1996. Incidence of opportunistic infection in intermediate and late states of HIV infection: the region of Bayamon, Puerto Rico experience. Fifth NIH Research Centers for Minority Institutions AIDS International Symposium, Rio Grande, Puerto Rico.

Rivera del Rio J, Flores R, Melendez J, Gomez MA, Vila S, Hunter R. 1996. Profile of HIV patients with or without endocarditis in Bayamon, PR. Fifth NIH Research Centers for Minority Institutions AIDS International Symposium, Rio Grande, Puerto Rico.

Thompson M, Creagh T, Harmon M, Rimland D, Lennox J, Toomey K. 1996. Impact on survival of combination or sequential antiretroviral therapy compared with AZT monotherapy. The Third Conference on Retroviruses and Opportunistic Infections, Washington, DC.

Vila S, Gomez M, Rios E, Hunter R. 1996. Moving trends of the epidemic in the Bayamon health region: the ambulatory experience. Fifth NIH Research Centers for Minority Institutions AIDS International Symposium, Rio Grande, Puerto Rico.

Ward J, Hanson D, Jones J, Kaplan J. 1996. Pneumococcal vaccination and the incidence of pneumonia among HIV-infected persons. Infectious Diseases Society of America 34th Annual Meeting, New Orleans, Louisiana.

1997

Buskin S, Sohlberg E, Hopkins S. 1997. Antiretroviral use, opportunistic illness (OI) prophylaxis, and OI incidence using data from the Adult/Adolescent Spectrum of HIV-Related Diseases study. Fourth Annual Joint Conference on Public Health, Washington State Public Health Association, Wenatchee, Washington.

Dascomb K, Clark R, Kissinger P, Didier E. 1997. A cross-sectional examination of clinical and demographic characteristics of HIV-infected patients with microsporidiosis. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, California.

Dascomb K, Clark R, Kissinger P, Didier E. 1997. Environmental exposures associated with microsporidiosis in HIV-infected patients. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, California.

Dascomb K, Didier E, Janney A, Kissinger P, Clark R. 1997. The prevalence of microsporidia in HIV-infected patients with symptoms of diarrhea. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, California.

Do A, Sullivan P, Li J, Jones J, Dworkin M, Wan P-C. 1997. Opportunistic illnesses at onset of clinical AIDS among young persons. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, California.

Dworkin M, Hanson D, Jones J, Adult and Adolescent Spectrum of Disease Project Group. 1997. Protease inhibitor usage and viral load monitoring among HIV-infected patients. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, California.

Dworkin M, Wan P-C, Jones J. 1997. Extrapulmonary tuberculosis in HIV-infected persons: Results from the Adult and Adolescent Spectrum of Disease Project. American Society for Tropical Medicine and Hygiene Conference, Orlando, Florida.

Gleckler E, Kissinger P, Mescally M, Kutzen H. 1997. Characteristics associated with hospice use among endstage AIDS patients. American Federation of Clinical Research, New Orleans, Louisiana.

Holding K, Dworkin M, Wan P-C, Jones J, Adult and Adolescent Spectrum of Disease Project Group. 1997. The spectrum of aspergillosis among HIV-infected persons. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, California.

Hunter R, Vila S, Gomez M. 1997. Mortality profile of AIDS patients in a Puerto Rican community. The Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC.

Inungu J, Morse A, Gordon C. 1997. Access to health services among HIV+ adolescents and young adults in New Orleans. Louisiana State University Medical Center Research Day, New Orleans, Louisiana.

Inungu J, Morse A, Gordon C. 1997. Anti-herpes treatment and the risk of Kaposi's Sarcoma in New Orleans. Louisiana State University Medical Center Research Day, New Orleans, Louisiana.

Inungu J, Morse A, Gordon C. 1997. Prevalence of sexually transmitted diseases among HIV-infected adolescents. National Conference on Women and HIV, Los Angeles, California.

Jones J, Hanson D, Dworkin M, Kaplan J, Ward J. 1997. Effect of therapy on CD4+ T-lymphocyte count at diagnosis of AIDS, 1991-1996. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, California.

Kaplan J, Hanson D, Jones J. 1997. Risk factors for primary PCP in HIV-infected adolescents and adults in the US: should history of AIDS-defining illness be included in the criteria for PCP prophylaxis? The Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC.

Michaels S, Kissinger P, Clark R, Beilke M. 1997. Clinical and treatment characteristics associated with the two log drop in viral load. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, California.

Newcomer L, Buskin S, Hopkins S. 1997. The effect of trimethoprim-sulfamethoxazole *Pneumocystis carinii* pneumonia (PCP) prophylaxis on bacterial illness, PCP, and death in persons with AIDS. Fourth Annual Joint Conference on Public Health, Washington State Public Health Association, Wenatchee, Washington.

Orr J, Clark RA, Kissinger P, Torres J, Robinson R. 1997. Characteristics associated with cervical invasive neoplasia among HIV-infected women. ISSTD, Seville, Spain.

Rivera del Rio J, Flores R, Melendez J, Gomez M, Vila S, Hunter R. 1997. Profile of HIV patients with or without endocarditis in Bayamon, P.R. The Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC.

Sullivan P, Hooper W, Dworkin M, Jones J. 1997. Venous thrombosis in HIV-infected patients: results from the multistate Adult and Adolescent Spectrum of HIV Disease Project. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, California.

Thompson M, Grochowski K, Melton D, Rimland D, Rossi T, Hill B. 1997. HIV-related opportunistic infections in patients with CD4+ counts >200 cells/ Φ L after potent antiretroviral therapy. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, California.

Welch K, Dascomb K, Wieland S, Kissinger P, Morse A. 1997. Survival patterns among HIV-infected patients diagnosed with anxiety, depression, and psychosis. Infectious Diseases Society of America 35th Annual Meeting, San Francisco, California.

1998

Agerton T, Wan P-C, Dworkin M, Jones J. 1998. Tuberculosis in HIV-infected women observed in the adult and adolescent spectrum of disease project. XII International Conference on AIDS, Geneva, Switzerland.

Bangdiwala S, Hunter R, Gomez M. 1998. Factors related to HIV+ versus AIDS presentation at the first contact with health services. The Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

Bazzano L, Dascomb K, Kissinger P, Butt A, DeSalvo K, Clark R. 1998. Epidemiologic features of the HIV-infected elderly. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California.

Beall G, Guerrero M, Kruger S, Saitoh A, Sorvillo F, Cheng K, Beall G, French C. 1998. HIV-associated pneumonias: the efficacy of pneumococcal vaccine (PV). XII International Conference on AIDS, Geneva, Switzerland.

Cohn D, Davidson A, Burman W, Coca V, Reves R, Rietmeijer C. 1998. Decreases in HIV-related morbidity, mortality, and health care utilization related to highly active antiretroviral therapy (HAART). XII International Conference on AIDS, Geneva, Switzerland.

Dascomb K, Clark R, Aberg J, Hewitt R, Pulvirenty J, Kissinger P, Didier E, Rogers L. 1998. Clinical characteristics of HIV-infected patients with microsporidiosis six months after primary diagnosis. The Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

Diamond C, Buskin S. 1998. HIV-infected American Indians/Alaskan Natives (AI/AN) in Seattle. Presentation at the 126th Annual Meeting and Exhibit of the American Public Health Association, Washington, DC.

Do A, Hanson D, Dworkin M, Jones J. 1998. Risk factors and trends of gonorrhea incidence among HIV-infected patients, United States. Infectious Diseases Society of America 36th Annual Meeting, Denver, Colorado.

Dworkin M, Hanson D, Jones J, Kaplan J, Ward, J, the Adult/Adolescent Spectrum of HIV Disease Project (ASD). 1998. Risk for primary *Pneumocystis carinii* pneumonia after the CD4+ T-lymphocyte count rises above 200 cells/uL. Infectious Diseases Society of America 36th Annual Meeting, Denver, Colorado.

Dworkin M, Sullivan P. 1998 *Bordetella bronchiseptica* infection in HIV-infected persons. XII International Conference on AIDS, Geneva, Switzerland.

Dworkin M, Wan P-C, Hanson D, Jones J. 1998. Factors associated with survival in HIV-infected patients with progressive multifocal leukoencephalopathy. The Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

Dworkin M, Wan P-C, Jones J. 1998. Recent patterns of antiretroviral prescription among HIV-infected patients in care in the United States. XII International Conference on AIDS, Geneva, Switzerland.

Horwitch C, Nolan C, Buskin S. 1998. Isoniazid preventive therapy in the PPD+/HIV+ population: adherence to recommendations. The 3rd Annual North American Regional Conference of the International Union Against Tuberculosis and Lung Disease, Vancouver, British Columbia, Canada.

Horwitch C, Nolan C, Kimball A, Buskin S. 1998. Isoniazid preventive therapy in the PPD+/HIV+ population: adherence to recommendations. Society of General Internal Medicine Annual Conference, Chicago, Illinois.

Inungu J, Clark R, Morse A, Gordon C, Dascomb K, Michaels S, Niccolai L. 1998. HIV infection and diabetes: clinical manifestations and survival. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California.

Jones J, Hanson D, Ward J. 1998. Effects of antiretroviral therapy on recent trends in cancers among HIV-infected persons. The Second National AIDS Malignancy Conference, Bethesda, Maryland.

Jones J, Hanson D, Dworkin M, Ward J, Jaffe H. 1998. Effects of antiretroviral and other antiviral therapy on the incidence of Kaposi's sarcoma and trends in Kaposi's sarcoma. XII International Conference on AIDS, Geneva, Switzerland.

McCombs S, Dworkin M, Wan P-C, Adult and Adolescent Spectrum of HIV Disease Project Group. Helminth infection in HIV-infected persons in the United States, 1990-1998. American Society for Tropical Medicine and Hygiene, San Juan, Puerto Rico. (meeting canceled).

McFarland F, Sackoff J, Su S, Singh T, Bryan E, Forlenza S. 1998. Impact of tuberculosis on immunocompromised HIV-infected persons in selected HIV clinics in New York City (NYC), 1991-1997. XII International Conference on AIDS, Geneva, Switzerland.

McNaghten A, Hanson D, Jones J, Dworkin M, Ward J. 1998. The effects of antiretroviral therapy and year of AIDS diagnosis on survival. XII International Conference on AIDS, Geneva, Switzerland.

McNaghten A, Hanson D, Jones J, Ward J, Dworkin M. 1998. The effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS. The Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

Michaels S, Clark R, Kissinger P. 1998. Differences in the incidence rates of opportunistic infections before and after the availability of protease inhibitors. The Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

Michaels S, Clark R, Kissinger P. 1998. Response to protease inhibitors after six months of treatment. Infectious Diseases Society of America 36th Annual Meeting, Denver, Colorado.

Michaels S, Huynh T, Kissinger P, Clark R. 1998. Characteristics associated with failure to receive protease inhibitors among HIV-infected individuals with a CD4+ count below 500 cells/dL. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California.

Niccolai L, Clark R, Kissinger P. 1998. Predictors of survival among patients with AIDS and disseminated *Mycobacterium avium* complex: the effect of MAC prophylaxis. Infectious Diseases Society of America 36th Annual Meeting, Denver, Colorado.

Ward J, Hanson D, Dworkin M, Jones J. 1998. The incidence and risk factors for bacterial pneumonia among HIV infected persons - United States. XII International Conference on AIDS, Geneva, Switzerland.

Welch K, Morse A, Kissinger P. 1998. Alcohol or drug use in HIV-infected patients. American Psychiatric Association Meeting on Psychiatric Services, Los Angeles, California.

1999

Bardugon J, Blais C, Slavinsky J, Kissinger P, Clark, R. Demographic and epidemiological characteristics of patients co-infected with hepatitis C virus and HIV. 1999. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania.

Blair J, Hanson D, Jones J, Dworkin M. 1999. Have pregnancy rates among human immunodeficiency virus (HIV)-infected women changed in the era of effective antiretroviral therapy to prevent perinatal transmission? 48th Annual Epidemic Intelligence Service Conference, Atlanta, Georgia.

Dworkin M, Wan P-C, Jones J, McCombs S. 1999. Patterns of antiretroviral prescription among HIV-infected patients in care in the United States. 1999 National HIV Prevention Conference, Atlanta, Georgia.

Dworkin M, Hanson D, Jones J, Kaplan J, Adult/Adolescent Spectrum of HIV Disease Project (ASD). 1999. The risk for *Pneumocystis carinii* pneumonia (PCP) and disseminated nontuberculous mycobacteriosis (dMb) after an antiretroviral therapy (ART) associated increase in the CD4+ T-lymphocyte count. The 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

Dworkin M., Hanson D, Ward J, Kaplan J, Jones J. 1999. Pneumococcal disease and the impact of pneumococcal vaccine in HIV-infected persons. 37th Annual Meeting of the Infectious Diseases Society of America (poster), Philadelphia, Pennsylvania.

Dworkin M, et al. 1999. *Entamoeba histolytica* infections among HIV-infected patients in the United States: clinical presentation, diagnostic methods, and treatment choices. 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC .

Inungu J, Morse A, Gordon C. 1999. Effect of clarithromycin and azithromycin prophylaxis on cryptosporidiosis occurrence among HIV+ patients. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania.

Jones J, Hanson D, Dworkin M, Kaplan J. 1999. Which opportunistic illnesses occur in the era of HAART and at what CD4 cell counts? The 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

Jones J, Hanson D, Dworkin M, DeCock K. 1999. HIV-associated TB in the era of HAART. 1999 National HIV Prevention Conference, Atlanta, Georgia.

Kaplan J, Hanson D, Dworkin M, Jones J. HIV plasma RNA, an independent predictor of opportunistic infections in HIV-infected persons, 1999. 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California.

Leonetti A, Barkan S, Hopkins S, Duchin J, Buskin S. 1999. Causes of death and factors associated with AIDS-related mortality in Seattle-King County, WA. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California.

McCarthy W, Gable J. 1999. A comparison of two methods for making inferences about the parameters of the logistic regression model. The 1999 Spring Meeting of the International Biometric Society Eastern North American Region, Biometric Bulletin, Atlanta, Georgia.

McCarthy W, Gable J, Lawrence J, Rimland D, Thompson M, the AIDS Research Consortium of Atlanta ASD Investigators. 1999. A case-control study to determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV-1 infected individuals. The 15th International Conference on Pharmacoepidemiology, Boston, Massachusetts.

McCarthy W, Gable J, Thompson M. 1999. Trends in malignancy incidence among HIV-infected individuals: the Atlanta, Georgia private care experience. The Third National AIDS Malignancy Conference, Bethesda, Maryland.

McCarthy W, Gable J, Lawrence J, Thompson M. 1999. Trends in pregnancy incidence among HIV-infected women and a description of the antiretroviral drugs prescribed to HIV-infected women during their pregnancies: the Atlanta, Georgia, Adult and Adolescent Spectrum of HIV Disease surveillance experience (1989 through 1998). 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania.

Pratt J, Wotring L, Mokotoff E. 1999. Differential rates of survival after AIDS diagnosis - Detroit Michigan. American Public Health Association Meeting, Chicago, Illinois.

Sackoff J, Shin S, Eden E, Peiper L. *Pneumocystis carinii* pneumonia associated with lack of medical care and nonadherence with prophylaxis. 1999. 1999 National HIV Prevention Conference, Atlanta, Georgia.

Slavinsky J, Lucille K, Kissinger P. 1999. Psychiatric care utilization among mentally ill and substance abusing patients at an inner city HIV outpatient clinic. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania.

Thompson M, Gable J, Lawrence J, Rimland D, McCarthy W, the AIDS Research Consortium of Atlanta ASD Investigators. 1999. The prevalence of hypertriglyceridemia in HIV infected individuals who have been exposed to various antiretroviral drug classes since January 1996. The 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

Welch K, Kissinger P, Morse A. 1999. Factors associated with substance use in HIV infected patients. AIDS Impact Conference, Ottawa, Canada.

2000

Blair J, Hanson D, Jones J, Dworkin M, Smith D, Denning P, Moorman A, DeCock K. 2000. Do gender differences in HIV-1 viral load predict differences in HIV disease progression? 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California.

Do A, Hanson D, Dworkin M, Jones, J. 2000. Risk factors and trends of gonorrhea incidence among HIV-infected patients, United States. 13th World AIDS Conference. Durban, South Africa.

Dworkin M, et al. 2000. Treatment of tuberculosis in HIV infected patients: a complicated course of therapy. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco.

Dworkin M, et al. 2000. The impact of trimethoprim-sulfamethoxazole prophylaxis for *Pneumocystis carinii* pneumonia on the risk for other infections in persons with AIDS. 13th World AIDS Conference. Durban, South Africa.

Fernandez-Santos D, Gomez M, Velazquez M, Mayor A, Gomez O, Hunter R. 2000. Survival of AIDS patients according to injecting drug use in a cohort of Puerto Rican AIDS patients. American Public Health Association 2000 Annual Meeting, Boston, Massachusetts.

Gomez M, Fernandez-Santos D, Velazquez M, Hunter R. HIV Transmission Mode Among Puerto Rican HIV/AIDS Women. 128th American Public Health Association Annual Meeting. November 12 - 16, 2000. Boston, MA.

Kellerman S, Hanson D, Dworkin M. 2000. Incidence of chronic hepatitis B infection in HIV infected individuals and the protective effect of Lamivudine: Data from the Adult/Adolescent Spectrum of HIV Disease (ASD) Project. Presentation at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Ontario, Canada.

Kellerman S, Hanson D, Dworkin M, Wortley P. 2000. Incidence of acute hepatitis B in HIV infected individuals and the protective effect of hepatitis B vaccination and lamivudine. Presentation at the 13th World AIDS Conference, Durban, South Africa.

Mayor A, Gomez M, Otero J, Hunter R. 2000. Pulmonary tuberculosis infection in a cohort of HIV/AIDS Puerto Rican Patients. American Public Health Association 2000 Annual Meeting, Boston, Massachusetts.

Updated February 6, 2003

McNaghten A, Hanson D, Dworkin M, Jones J, Adult/Adolescent Spectrum of HIV Disease Project Group. 2000. Inequities among persons with psychological and social illnesses in prescription of highly active antiretroviral therapy. United States Conference on AIDS, Atlanta, Georgia.

McNaghten A, Hanson D, Dworkin M, Jones J, Adult/Adolescent Spectrum of HIV Disease Project Group. 2000. Inequities between gender and racial groups in prescription of highly active antiretroviral therapy. 13th World AIDS Conference, Durban, South Africa.

Pratt J, Gillespie B, Boulton M, Wotring L, Mokotoff E, James S. 2000. Evaluation of the 1993 AIDS case surveillance definition since the introduction of HAART. Infectious Disease Society of America Meeting, New Orleans, Louisiana.

Schuchat A, et al. 2000. Observational studies of pneumococcal polysaccharide vaccine (PPV) effectiveness among HIV-infected adults, USA, 1990 - 1998. The Second International Symposium on Pneumococci and Pneumococcal Diseases, Sun City, South Africa.

Shin S, Sackoff J. 2000. Advanced immune suppression among foreign-born HIV-infected patients initiating care at three New York City HIV clinics. 13th World AIDS Conference, Durban, South Africa.

Sullivan P, Dworkin M. 2000. Incidence and associations of fatigue in HIV-infected persons. 13th World AIDS Conference, Durban, South Africa.

Welch K, Morse A, Gordon C. 2000. Virological response to highly active antiretroviral therapy (HAART) among HIV-positive: Individuals diagnosed with mental illness or substance illness. AMFAR 12th National HIV/AIDS Update Conference, San Francisco, California.

2001

Blair J, Hanson D, Jones J, Dworkin M. 2001. Have pregnancy rates in human immunodeficiency virus-infected women changed in the era of effective antiretroviral therapy for prevention of perinatal transmission? The 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

Fernandez D, Gomez M, Otero J, Hunter H. Survival of AIDS Patients According to Heterosexual Transmission Mode in Puerto Rican AIDS Patients. 2001 National HIV Prevention Conference. August 12 - 15, 2001. Atlanta, GA.

Kaplan J, Hanson D, Karon J, Cohn D, Thompson M, Buskin S, Fleming P, Dworkin M. 2001. Late initiation of antiretroviral therapy (at CD4+ lymphocyte count <200 cells/uL) is associated with increased risk of death. The 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

Mayor A, Vila L, De La Cruz M, Gomez R. Clinical Outcomes of Systemic Lupus Erythematosus Patients Treated in a Managed Care System Versus a Fee for Service System. 129th American Public Health Association Annual Meeting. October 21 - 25, 2001. Atlanta, GA.

McNaghten A, Hanson D, Dworkin M, Adult/Adolescent Spectrum of HIV Disease Project Group. 2001. Differences in prescription of highly active antiretroviral therapy persist in 1999. The 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

McNaghten A, Hanson D, Nakashima A, Swerdlow D. Declines in AIDS-defining opportunistic illnesses level off from 1998 to 1999. IDSA 2001 Conference, San Francisco, California.

Sackoff J, Shin S, Weedon J. 2001. Achievement and durability of viral suppression in patients prescribed HAART in HIV clinics in New York City. The 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.

2002

Amill A, Gomez M, Fernandez D, Baez D, Hunter R. Changes in the Sociodemographic, Risk and Clinical Profile of a Male Injecting Drug Use Puerto Rican Population Arriving With Criteria for AIDS in the Bayamón Region of Puerto Rico, From 1992 to 2000. 1^{ra} Conferencia Puertorriqueña de Salud Pública. April 10 - 12, 2002. San Juan, PR.

Amill A, Baez D, Gomez M, Mayor A, Fernandez D, Hunter R. Changing trends among males injecting Drug users with AIDS in Bayamón, Puerto Rico. 8th RCM International Symposium on Health Disparities. December 8-11, 2002. Honolulu, Hawaii.

Baez D, Gomez M, Fernandez D, Velasquez M, Hunter R. Moving Trends in the Psychosocial and Clinical Profile of a Puerto Rican Cohort of AIDS Patients Between Years 1992 and 2000 at First Encounter. 1^{ra} Conferencia Puertorriqueña de Salud Pública. April 10 - 12, 2002. San Juan, PR.

Baez D, Gomez M, Fernandez D, Velazquez M, Amill A, Hunter R. Profile of HIV patients with and without toxoplasmosis of brain: Findings from cohort of Puerto Rican Patients. 130th APHA Annual Meeting & Exposition. November 9-13, 2002. Philadelphia, PA

Baez D, Gomez M, Fernandez D, Mayor A, Velazquez M, Hunter R. Sociodemographics and clinical profile moving trends between 1992-2001 in a Puerto Rican cohort of AIDS patients, at first encounter. 8th RCM International Symposium on Health Disparities. December 8-11, 2002. Honolulu, Hawaii.

Brooks J, Adams M, McNaghten AD, Swerdlow D. *Streptococcus pneumoniae* (Sp) in HIV-infected adults: risk for infection and antimicrobial susceptibilities. International AIDS Conference, July 7-12, Barcelona, Spain.

Updated February 6, 2003

Brooks J, Hanson D, McNaghten AD, Swerdlow D. Low CD4 count predicts less durable virologic response to highly active antiretroviral therapy (HAART) in naïve patients. International AIDS Conference, July 7-12, Barcelona, Spain.

Cohn DL, Breese PS, Burman WJ, Lopez DL, Barth BL, Rietmeijer CA, Davidson AJ, Denver Public Health, Denver, United States. Continued benefit from highly active antiretroviral therapy: trends in AIDS-related opportunistic illnesses in a public health care system, 1990-2000. International AIDS Conference, July 7-12, Barcelona, Spain.

Fernandez D, Gomez M, Báez D, Velazquez M, Hunter R. Factors Related with Clinical Depression among a Cohort of Puerto Rican HIV/AIDS Patients. 1^{ra} Conferencia Puertorriqueña de Salud Pública. April 10 - 12, 2002. San Juan, PR.

Fernandez D, Gomez M, Mayor A, Baez A, Amill A, Hunter R. Changes in depression score among a cohort of HIV/AIDS Puerto Rican patients. 8th RCMi International Symposium on Health Disparities. December 8-11, 2002. Honolulu, Hawaii.

Kellerman SE, Hanson D, McNaghten AD. Incidence of acute hepatitis B (HBV) infection in HIV infected persons and the impact of HB vaccination and lamivudine. 9th Conference of Retroviruses and Opportunistic Infections, February 24-28, 2002, Washington State Convention and Trade Center, Seattle, WA.

Lu S, Wohl A, Turner J, Bunch G. Comparison of OI incidence in HIV-infected women with and without a history of substance abuse in the pre- and post-HAART era in Los Angeles County. APHA 2002, November 9-13, Philadelphia, PA

Mayor A, Gomez M, Hunter R. Non-Hodgkin's Lymphoma in a Cohort of HIV/AIDS Patients in Puerto Rico. 130th APHA Annual Meeting & Exposition. November 9-13, 2002. Philadelphia, PA.

Mayor A, Gomez M, Hunter R. Recurrent pneumonia mortality risk in a cohort of HIV/AIDS patients in Puerto Rico. 8th RCMi International Symposium on Health Disparities. December 8-11, 2002. Honolulu, Hawaii.

Mayor A, Vila L. Gender differences in clinical manifestations, serological findings and outcome in a cohort of Puerto Ricans with systemic lupus erythematosus. 8th RCMi International Symposium on Health Disparities. December 8-11, 2002. Honolulu, Hawaii.

Mayor A, Gomez M, Hunter R. Differences between non-hodgkin's lymphomas in a cohort of HIV/AIDS patients in Puerto Rico. 8th RCMi International Symposium on Health Disparities. December 8-11, 2002. Honolulu, Hawaii.

McNaghten AD, Hanson DL, Kellerman SE, Blair JM, and the Adult/Adolescent Spectrum of HIV Disease Project Group. Factors associated with immunologic stage at which patients initiate antiretroviral therapy. 9th Conference of Retroviruses and Opportunistic Infections, February 24-28, 2002, Washington State Convention and Trade Center, Seattle, WA.

McNaghen AD, et al. Differences in receipt of antiretroviral therapy by sex, race and insurance status: a comparison of data from three studies. International AIDS Conference, July 7-12, Barcelona, Spain.

Peterson KL, Burman WJ, Yun LW, Cohn DL, Davidson AJ, Denver Public Health, Denver, United States. When to start? The effect of adherence on disease progression after the initiation of combination antiretroviral therapy. International AIDS Conference, July 7-12, Barcelona, Spain.

Pfeiffer MR, Sackoff J, Bernard MA, Bryan E, Raj-Singh S, New York City Department of Health, HIV/AIDS Surveillance Program, New York, NY, United States. Rates of testing for Hepatitis C virus in HIV-infected injecting drug users receiving medical care. International AIDS Conference, July 7-12, Barcelona, Spain.

Rietmeijer CAM, Davidson AJ, Cohn DL, Denver Public Health, Denver, United States. HIV-related health care utilization and charges in a public health care facility: trends in relation to the introduction of highly active antiretroviral therapy (HAART). International AIDS Conference, July 7-12, Barcelona, Spain.

Smith A, Williamson J, Wolfe M, Swerdlow D, Dworkin M. Failure to demonstrate protection from pneumococcal disease with trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis among AIDS patients with very low CD4 counts. International AIDS Conference, July 7-12, Barcelona, Spain.

Teshale EH, Kellerman SE, Adams MR, Wolfe MI, Swerdlow DL. Adherence to guidelines among HIV/HCV co-infected persons and providers. 9th Conference of Retroviruses and Opportunistic Infections, February 24-28, 2002, Washington State Convention and Trade Center, Seattle, WA.

Vila L, Mayor A. Clinical relevance and prognostic value of autoantibodies in Puerto Ricans with systemic lupus erythematosus. 8th RCM International Symposium on Health Disparities. December 8-11, 2002. Honolulu, Hawaii.

Wolfe MI, Selik RM, Adams MR, Swerdlow DL, and the Adult and Adolescent Spectrum of HIV Disease Project Investigators. Changes in proportions of clinical diagnoses present at death in HIV-infected persons since the advent of highly active antiretroviral therapy (HAART). 9th Conference of Retroviruses and Opportunistic Infections, February 24-28, 2002, Washington State Convention and Trade Center, Seattle, WA.

Wolfe MI, Selik RM, Adams MR, Swerdlow DL, and the Adult and Adolescent Spectrum of HIV Disease Project Investigators. Changes in diagnoses present at death among HIV-infected persons since the advent of HAART. International AIDS Conference, July 7-12, Barcelona, Spain.